Protocol Ledger

NCT03583710 · Phase III · RECRUITING

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Interventional Phase III clinical trial protocol NCT03583710 sponsored by MD Anderson Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-20 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03583710
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03583710
Protocol FieldVerified Registry Value
NCT IdentifierNCT03583710
Consolidated Lead SponsorMD Anderson Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2018-08-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for MD Anderson Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI